PART I / OGM – Institutions resist, but Progress
Post# of 61
(Total Views: 50)
Posted On: 05/07/2025 8:16:19 PM
PART I / OGM – Institutions resist, but Progress is Unstoppable!
There are signs of institutional bias and fixed reliance on traditional methods like PCR and FISH that slow OGM’s adoption.
Despite multiple peer-reviewed studies showcasing OGM’s effectiveness, the FDA has yet to grant full regulatory approval, delaying its integration into clinical diagnostics.
Many clinical labs still rely on older techniques like chromosome banding, FISH, and microarrays, even though they have well-documented limitations.
While OGM is gaining traction internationally, U.S. adoption remains sluggish, possibly due to corporate interests protecting existing sequencing technologies.
Unlike traditional sequencing methods, OGM has not yet received widespread backing from large pharmaceutical companies, which may be hesitant to disrupt their established workflows.
While there’s no outright evidence of Big Pharma actively blocking OGM, the slow adoption and regulatory delays suggest that current industry forces may be reluctant to embrace new and improved technology.
There are signs of institutional bias and fixed reliance on traditional methods like PCR and FISH that slow OGM’s adoption.
Despite multiple peer-reviewed studies showcasing OGM’s effectiveness, the FDA has yet to grant full regulatory approval, delaying its integration into clinical diagnostics.
Many clinical labs still rely on older techniques like chromosome banding, FISH, and microarrays, even though they have well-documented limitations.
While OGM is gaining traction internationally, U.S. adoption remains sluggish, possibly due to corporate interests protecting existing sequencing technologies.
Unlike traditional sequencing methods, OGM has not yet received widespread backing from large pharmaceutical companies, which may be hesitant to disrupt their established workflows.
While there’s no outright evidence of Big Pharma actively blocking OGM, the slow adoption and regulatory delays suggest that current industry forces may be reluctant to embrace new and improved technology.
(0)
(0)